Horizon Discovery Group plc to Acquire CombinatoRx Service Business and Assets from Zalicus Inc.
Horizon Discovery Group plc has agreed to acquire the CombinatoRx service business (known as the combination high throughput screening (cHTS) business) and related assets from Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, for £4.74 million ($8.0 million USD). The new business will become Horizon CombinatoRx Incorporated, a wholly owned subsidiary of Horizon.
Horizon CombinatoRx will provide access to the unique cHTS platform and Chalice analytics software, which enables the screening and analysis of thousands of complementary drug combinations. By combining the cHTS platform with Horizon’s GENESIS (rAAV, CRISPR & ZFN) gene editing platform and X-MAN isogenic cell line technology, Horizon CombinatoRx will be able to offer services including novel phenotypic cell-based screens with compound siRNA, shRNA and sgRNA (for CRISPR based screening) libraries.
These new services will offer a powerful solution for drug discovery and development organizations to explore the efficacy and mechanistic synergies of thousands of drug combinations, with the potential to identify personalized medicine regimens for the treatment of serious diseases. The business will benefit from expansion of its historical customer base in North America to Europe, Japan and beyond via access to Horizon’s business development infrastructure and an 800+ strong customer base.
Combination therapies are emerging as the standard of care in indications such as cancer, inflammation, diabetes, and infectious disease. The current approach for developing combination therapies at the clinical stage misses the opportunity to identify novel multi-target mechanisms that better address the systems biology of disease and the emergence of resistance. The new services offered by Horizon CombinatoRx address this need by providing a scalable, high throughput combination screening platform, alongside Horizon’s gene editing and drug discovery and development expertise.
The assets acquired by Horizon, developed through a cumulative R&D investment of more than $30 million, include two fully integrated robotic screening platforms optimized for combination screening, outstanding customer contracts, the Chalice informatics platform, a highly characterized library of approximately 800 cell lines, and an extensive compound and chemical probe library. Horizon CombinatoRx, Inc. will be located in 23,000 sq. ft. of laboratory and office space in Kendall Square, Cambridge, MA, providing a base for future growth of Horizon business operations in North America.
Jeb Ledell, Vice President of Corporate Operations, Zalicus Inc. will become Chief Operating Officer of the subsidiary, Horizon CombinatoRx Inc., and will lead a dedicated operations and R&D team with decades of experience in combination sciences. Horizon’s Lydia Meyer Turkson will become Vice President (US) Business Development.
“We have been very impressed by the scientific excellence, passion and resilience of the CombinatoRx service business over many years, and we are delighted to have agreed to acquire the business and assets from Zalicus,” commented Dr Darrin M Disley, Chief Executive Officer of Horizon Discovery Group plc. “The scalable and proven cHTS and Chalice platform combined with our world-leading translational genomics technologies significantly broadens the portfolio of discovery research services we can offer to our global customer base. We look forward working with the CombinatoRx team to provide science-driven solutions that will add real value to our customers’ research.”
“I am pleased that Horizon recognizes the value of the cHTS platform, said Mark H.N. Corrigan, MD, President and Chief Executive Officer of Zalicus. “Importantly, if closed, the sale of cHTS, will increase our cash balance and should provide Zalicus shareholders with a greater ownership position in our previously-announced merger with Epirus Biopharmaceuticals.“
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance